Consequently, sphingomyelin supplementation or targeting the ASM/ceramide system may recover, at least to some extent, disrupted lipid rafts and α7nAchR function, and may thereby potentially benefit patients with schizophrenia. The gene discussed is CHRNA7; the disease is schizophrenia.